T. Rowe Price Associates’s Sanara MedTech SMTI Stock Holding History

T. Rowe Price Associates’s Portfolio SMTI Stock Details SMTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$455K	Buy	19,252 +8,354	+77%	+$173K	﹤0.01%	2664
2026 Q1	$188K	Buy	10,898 +2,200	+25%	+$45.3K	﹤0.01%	2864
2025 Q4	$204K	Buy	8,698 +2,100	+32%	+$54.2K	﹤0.01%	2801
2025 Q3	$210K	Buy	+6,598	New	+$199K	﹤0.01%	2776
2025 Q1	–	Sell	-6,237	Closed	-$208K	–	3072
2024 Q4	$208K	Buy	+6,237	New	+$212K	﹤0.01%	2665
2024 Q2	–	Sell	-5,805	Closed	-$215K	–	3020
2024 Q1	$215K	Buy	5,805 +322	+6%	+$12K	﹤0.01%	2589
2023 Q4	$226K	Buy	+5,483	New	+$176K	﹤0.01%	2489
2023 Q3	–	Sell	-5,371	Closed	-$216K	–	2910
2023 Q2	$216K	Buy	+5,371	New	+$220K	﹤0.01%	2500
2023 Q1	–	Sell	-5,900	Closed	-$268K	–	2948
2022 Q4	$268K	Buy	+5,900	New	+$203K	﹤0.01%	2412

Other funds holding SMTI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

SWM

Stonebridge Wealth Management Oak Brook, Illinois $112M AUM 23.07% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

T. Rowe Price Associates's SMTI Position: Q2 2026 in Review

T. Rowe Price Associates increased its Sanara MedTech (SMTI) stake by 77% in Q2 2026, buying an estimated $173K and bringing the position to 19,252 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

T. Rowe Price Associates first reported a position in SMTI in Q4 2022 and has held it in 9 quarters since. 74 funds tracked by Wall St. Rank hold SMTI as of Q2 2026.

T. Rowe Price Associates held 19,252 shares of Sanara MedTech worth $455K as of Q2 2026.
T. Rowe Price Associates bought 8,354 Sanara MedTech shares in Q2 2026, an estimated $173K.
Sanara MedTech made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2664 holding.
T. Rowe Price Associates first reported a position in Sanara MedTech in Q4 2022 and has held it in 9 quarters since.
74 funds tracked by Wall St. Rank held Sanara MedTech as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.